ArticleScientific reports2025
Unveiling the mechanisms and promising molecular targets of curcumin in pancreatic cancer through multi-dimensional data.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The potential value of curcumin in breast cancer: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is a highly aggressive and fatal malignancy, primarily affecting older males. Curcumin, a potential anti-cancer agent, has been shown to regulate key molecules in cancer progression, but its specific mechanisms in PC remain unclear. We conducted a comprehensive database search to identify curcumin-related targets in PC. Gene expression and immune correlations were analyzed using the GEO database, identifying differentially expressed hub genes (DEHGs). A method involving machine learning was employed to identify feature genes and create a nomogram, using external datasets and molecular docking for preliminary validation. Consensus clustering and subgroup comparisons were also performed based on DEHGs expression. We identified 35 DEHGs strongly associated with immune cell infiltration. Five feature genes (VIM, CTNNB1, CASP9, AREG, HIF1A) were used to build a nomogram, with the classification model showing AUC values above 0.9 in both training and validation groups. Molecular docking highlighted potential binding sites of five feature genes for curcumin. Clustering analysis categorized PC samples into four distinct subgroups: C1 and CII, which showed high expression and elevated immune cell infiltration, and C2 and CI, which exhibited the opposite pattern. Significant variations in scores of DEHG were seen between C1 and C2, in addition to between CI and CII. Curcumin may target DEHGs to influence PC, regulating immune and tumor proliferation mechanisms. These outcomes provide potential insights for medical applications and upcoming research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.